Mometazonfuroat Cipla (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometazonfuroat Cipla, is a corticosteroid presented as a nasal spray formulation for nasal use. It treats allergic rhinitis and nasal polyps by reducing inflammation in the nasal passages. GNH USA supplies Mometazonfuroat Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate is a nasal corticosteroid that reduces inflammation in the upper respiratory tract.

- Allergic rhinitis: relieves nasal congestion, itching, sneezing, and rhinorrhea. - Nasal polyps: decreases polyp size and improves nasal airflow. - Seasonal allergic rhinitis: helps prevent onset of nasal symptoms during pollen season.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Throat irritation or dryness. - Cough. - Altered taste or bitter aftertaste.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Vision changes such as cataracts or glaucoma. - Adrenal suppression with prolonged high‑dose use. - Opportunistic fungal infection of the nasal mucosa. - Persistent or worsening nasal bleeding.

Before using Mometazonfuroat Cipla, consider the following safety measures. - Pregnancy: consult a healthcare professional before initiating therapy. - Children: dosing and safety should be evaluated by a pediatric specialist. - Recent nasal surgery: increased risk of postoperative bleeding. - Concurrent systemic corticosteroids: monitor for additive glucocorticoid effects. - Immunocompromised patients: higher susceptibility to local infections. - Store at room temperature: keep in the original container, protect from moisture and heat.

Mometasone furoate may interact with other medications; review the following.

Major Interactions (Avoid): - Systemic corticosteroids: may increase overall glucocorticoid exposure and risk of systemic effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise local drug concentrations.

Moderate Interactions (Monitor Closely): - Antihistamines: may exacerbate nasal dryness. - Other intranasal agents (e.g., antifungal sprays): could affect absorption or irritation. - Live vaccines: consider timing of administration relative to steroid use.